AbbVie (ABBV) and Roche (RHHBY.OB) have halted five studies of their ABT-199 drug for leukemia...

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

AbbVie (ABBV) and Roche (RHHBY.OB) have halted five studies of their ABT-199 drug for leukemia and lymphoma after two patients died of tumor lysis syndrome, when the rapid destruction of malignant cells causes acute kidney failure. The firms are working to refine the dose to overcome the problem and hopes to start Phase III testing of ABT-199 this year, as planned.